Orion has opened enrollment for TEADCO, a multicenter, open-label Phase 1b/2 basket trial testing its oral pan-TEAD inhibitor ODM-212 in combination settings across three solid tumors. The study includes first-line malignant pleural mesothelioma with ipilimumab plus nivolumab, KRAS G12C–mutated non-small cell lung cancersmall cell lung cancer with sotorasib in both inhibitor-naïve and inhibitor-pretreated cohorts, and metastatic pancreatic adenocarcinoma with nab-paclitaxel plus gemcitabine. The trial is structured to evaluate safety, dose selection, tolerability, and preliminary efficacy of each combination.
The move signals Orion’s intent to prosecute the TEAD mechanism where the Hippo/YAP–TAZ axis is implicated in primary tumor biology and, critically, in acquired resistance to standard therapies. Mesothelioma offers a biologically rational starting point given the frequency of Hippo pathway alterations such as NF2 loss. In KRAS G12C NSCLC, TEAD inhibition targets a well-characterized resistance node that emerges under selective pressure from KRAS inhibitors. In pancreatic cancer, the goal is additive benefit to a chemotherapy backbone in an indication with minimal headroom for incremental toxicity. Running combination cohorts alongside an ongoing monotherapy program positions Orion to triangulate both direct anti-tumor activity and resistance-modifying effects and to pivot quickly toward the most responsive biology.
Operationally, this is an ambitious configuration that will test the company’s early-phase execution. Each arm will require a dedicated safety run-in to establish a regimen-specific RP2D, with close attention to overlapping and mechanism-related toxicities. The ipilimumab/nivolumab triplet raises clear immunotherapy management considerations, including steroid use that can confound pharmacodynamic readouts. The sotorasib combination introduces drug–drug interaction and hepatotoxicity monitoring burdens, and the chemotherapy arm layers myelosuppression and neuropathy on top of a first-in-class mechanism. Sites will need tight coordination of PK/PD sampling, imaging cadence across heterogeneous tumor types, and biopsies to support pathway engagement analyses.
Recruitment dynamics will not be trivial. Mesothelioma volumes are concentrated at specialized centers with heavy competition for first-line immunotherapy-based trials. In NSCLC, the post–KRAS inhibitor cohort addresses a clinical gap but is already a crowded segment, with sponsors vying for patients who often progress quickly and may be less trial-eligible. KRAS G12C–naïve patients are more accessible but come with higher expectations for response benchmarks. Pancreatic cancer accrual is feasible but fragile, with performance status deterioration and site logistics frequently driving screen failures. Orion’s site strategy will need targeted molecular prescreening for KRAS status, pragmatic biopsy requirements, and streamlined adverse event workflows to compete.
Regulatory expectations are equally clear. Basket designs can accelerate signal detection, but regulators will expect arm-by-arm dose justification, prospective safety oversight, and biomarker-driven analyses that connect response to Hippo pathway activation. Incorporating NF2 status in mesothelioma, YAP/TAZ localization, TEAD palmitoylation markers, and ctDNA dynamics could de-risk advancement decisions and support dialogue on expansion cohorts. A clean DLT profile and manageable transaminase, dermatologic, and GI signals will be prerequisites before Orion can scale any arm into a registrational trajectory.
Near term, the key readouts will be tolerability and RP2D selection per cohort, followed by early response and disease control signals—particularly in KRAS G12C–pretreated NSCLC and first-line mesothelioma. Watch for how Orion prioritizes indications, whether it enriches based on Hippo-pathway biomarkers, and how quickly it moves from signal-finding to expansion. Also notable will be any adjustments in partner backbones as the KRAS landscape evolves and as immunotherapy triplets face real-world toxicity. The central question is whether TEAD inhibition can deliver clinically meaningful resistance modulation without eroding operational feasibility—a balance that will determine if this mechanism graduates from promising biology to prosecutable development path.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
